Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study

Blood (2021) 138 (Supplement 1): 369.

DOI: https://doi.org/10.1182/blood-2021-150371

Published: 2021

Journal Articles

Dose Reductions and Discontinuations with Chronic Lymphocytic Leukemia (CLL) Patients Receiving Ibrutinib in Community and Academic Settings

Jing-Zhou Hou, MD PhD, Kellie Ryan, MPH, Senxi Du, Bruno S. Fang, MD, Stanley M. Marks, MD, Ray Page, Eileen Peng, PharmD, Keith Szymanski, Sharon Winters, Hannah Le, PharmD, MPH

Blood (2020) 136 (Supplement 1): 12–13.

DOI: https://doi.org/10.1182/blood-2020-139951

Published: 2020

Journal Articles

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Anastasia Tsagianni, MD, Konstantinos Lontos, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic J. Farah, MD, Robert L. Redner, MD, Annie Im, MD, Kathleen A. Dorritie, MD, Alison R. Sehgal, MD, James M. Rossetti, DO, Melissa Saul, MS, William Gooding, MS, Michael Boyiadzis, MD

Blood (2020) 136 (Supplement 1): 33–34.

DOI: https://doi.org/10.1182/blood-2020-138561

Published: 2020

Journal Articles

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Blood (2020) 135 (24): 2137–2145.

DOI: https://doi.org/10.1182/blood.2020004856

Published: 2020

Includes: Supplemental data

Journal Articles

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Asha Ricciuti, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic Farah, MD, Robert L. Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, James M. Rossetti, DO, Yongli Shuai, PhD, Daniel Normolle, PhD, Rahim Remtulla, MD, Shawn Tahata, MD, Michael Boyiadzis, MD, Annie Im, MD

Blood (2018) 132 (Supplement 1): 4000.

DOI: https://doi.org/10.1182/blood-2018-99-113935

Published: 2018

Journal Articles

Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy

Andrew Wei, MD, Stephen A. Strickland, MD, Jing-Zhou Hou, MD PhD, Walter Fiedler, MD, Tara L Lin, MD, Roland B. Walter, MDPhDMS, Anoop K Enjeti, MBBS,FRCPA,MDMRCP, Wan-Jen Hong, Brenda Chyla, Relja Popovic, PhD, Kaffa Fakouhi, Tu Xu, PhD, John Hayslip, Gail J. Roboz, MD

Blood (2018) 132 (Supplement 1): 284.

DOI: https://doi.org/10.1182/blood-2018-99-118729

Published: 2018

Journal Articles

Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes

Andrew Wei, MBBS, PhD FRACP, FRCPA, Stephen A. Strickland, MD MSCI, Gail J. Roboz, MD, Jing-Zhou Hou, MD PhD, Walter Fiedler, MD, Tara L. Lin, MD, Roland B. Walter, MD PhD, Anoop Enjeti, MD MRCP, FRCPA, MClin Epid, GradCert Bioethics, Brenda Chyla, PhD, Relja Popovic, PhD, Kaffa Fakouhi, Pooja Shah, Martin Dunbar, DRPH, MS, Tu Xu, PhD, Mack Mabry, MD, John Hayslip, MD MSCR

Blood (2017) 130 (Suppl_1): 890.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.890.890

Published: 2017

Journal Articles

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Michael Boyiadzis, MD MHSc, Mounzer Agha, MD, Robert L Redner, MD, Alison Sehgal, MD, Annie Im, MD, Jing-Zhou Hou, Rafic Farah, MD, Kathleen A. Dorritie, MD, Anastasios Raptis, MD PhD, Seah H. Lim, MDPhDFRCP,FRCPath,MBBS, Hans Klingemann, MD PhD, Hong Wang, PhD, Natalia Lapteva, PhD, Mei Zhuyong, MD, Lisa H Butterfield, PhD, Cliona M. Rooney, PhD, Theresa L Whiteside, PhD

Blood (2016) 128 (22): 1649.

DOI: https://doi.org/10.1182/blood.V128.22.1649.1649

Published: 2016

Journal Articles

Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study

Ajay K. Gopal, MD, Stephen J. Schuster, MD, Nathan Fowler, MD, Judith Trotman, MBChB, Georg Hess, MD, Jing-Zhou Hou, Abdulraheem Yacoub, MD, Michael Lill, MD BS, Peter Martin, MD, Umberto Vitolo, MD, Wojciech Jurczak, MD, James Morton, MBBS, BSc(MD, FRACP, FRCPA, Dzhelil Osmanov, MD, Gary J. Gartenberg, MD, Jessica Vermeulen, MD PhD, Sriram Balasubramanian, PhD, Shean-sheng Wang, PhD, Sanjay Deshpande, MD, Gilles A. Salles

Blood (2016) 128 (22): 1217.

DOI: https://doi.org/10.1182/blood.V128.22.1217.1217

Published: 2016

Journal Articles

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia

Andrew Wei, Stephen A. Strickland, Gail J. Roboz, Jing-Zhou Hou, Walter Fiedler, MD, Tara L. Lin, Giovanni Martinelli, Roland B. Walter, MD PhD, Anoop Enjeti, Kaffa Fakouhi, David E. Darden, Martin Dunbar, Ming Zhu, Suresh Agarwal, Ahmed H. Salem, Mack Mabry, John Hayslip

Blood (2016) 128 (22): 102.

DOI: https://doi.org/10.1182/blood.V128.22.102.102

Published: 2016

Journal Articles

Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study

Gilles A. Salles, Judith Trotman, MB ChB, Michael Lill, MD BS, Bruce Cheson, MD, Stephen J. Schuster, MD, Jing-Zhou Hou, John A Radford, MB ChB, MRCP, MD FRCP, Andrew Spencer, Michael Schaffer, PhD, Rajendra Damle, PhD, Gary J. Gartenberg, MD, Jessica Vermeulen, MD PhD, Sriram Balasubramanian, PhD, Sanjay Deshpande, MD, Dolores Caballero, MD PhD

Blood (2016) 128 (22): 2980.

DOI: https://doi.org/10.1182/blood.V128.22.2980.2980

Published: 2016

Journal Articles

Phase 2 Study of Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Annie Im, MD, Mounzer Agha, MD, Anastasios Raptis, MD PhD, Jing-Zhou Hou, MD PhD, Rafic Farah, MD, Seah H. Lim, MDPhDFRCP,FRCPath,MBBS, Robert Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, Ann Welsh, RN, BSN, OCN, Linda Fukas, RN, Christine Tripoli, RN, BSN, Daniel Normolle, PhD, Daniel E Johnson, PhD, Michael Boyiadzis, MD MHSc

Blood (2015) 126 (23): 3739.

DOI: https://doi.org/10.1182/blood.V126.23.3739.3739

Published: 2015

Journal Articles

Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Annie Im, MD, Jing-Zhou Hou, MD PhD, Anastasios Raptis, MD, Mounzer Agha, MD, Rafic Farah, MD, Robert L. Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, Ann Welsh, RN, Daniel E. Johnson, PhD, Daniel Normolle, PhD, Michael Boyiadzis, MD

Blood (2014) 124 (21): 2265.

DOI: https://doi.org/10.1182/blood.V124.21.2265.2265

Published: 2014

Journal Articles

Outcomes of Hematopoietic Cell Transplantation in Patients with Refractory Acute Myeloid Leukemia

Annie Im, MD, Navkiranjit Gill, DO, Diana Cunningham, MS, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD, PhD, Robert L. Redner, MD, Julie Phillips, MSN, CRNP, BC, Michael Boyiadzis, MD, MHSc

Blood (2012) 120 (21): 4531.

DOI: https://doi.org/10.1182/blood.V120.21.4531.4531

Published: 2012

Journal Articles

A Randomized Clinical Trial of Lenalidomide and Dexamethasone with and without Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Interim Study Results,

Blood (2011) 118 (21): 4142.

DOI: https://doi.org/10.1182/blood.V118.21.4142.4142

Published: 2011

Journal Articles

Differential impact of mammalian target of rapamycin inhibition on CD4 + CD25 + Foxp3 + regulatory T cells compared with conventional CD4 + T cells

Robert Zeiser, Dennis B. Leveson-Gower, Elizabeth A. Zambricki, Neeraja Kambham, Andreas Beilhack, John Loh, Jing-Zhou Hou, Robert S. Negrin

Blood (2008) 111 (1): 453–462.

DOI: https://doi.org/10.1182/blood-2007-06-094482

Published: 2008

Journal Articles

Selective Expansion of Human Regulatory (CD4+CD25+CD127LowFOXP3+) Cells to High Purity by Inhibiting Expansion of CD4+CD25+CD127HighFOXP3-Conventional T Cells with Rapamycin.

Jing-Zhou Hou, MD, PhD, Elizabeth Zambricki, MS, Robert Zeiser, MD, Robert S. Negrin, MD

Blood (2006) 108 (11): 3162.

DOI: https://doi.org/10.1182/blood.V108.11.3162.3162

Published: 2006

Journal Articles

Early CD30 Signaling Is Critical for Adoptively Transferred CD4 + CD25 + Regulatory T Cells in Prevention of Acute Graft Versus Host Disease.

Robert Zeiser, MD, Vu H. Nguyen, M.D., Jing-Zhou Hou, M.D. Ph.D., Andreas Beilhack, M.D., Elizabeth A. Zambricki, Martin Buess, M.D. Ph.D., Christopher H. Contag, Ph.D., Robert Negrin, M.D.

Blood (2006) 108 (11): 3176.

DOI: https://doi.org/10.1182/blood.V108.11.3176.3176

Published: 2006

Journal Articles

Impact of mTOR Inhibition on FoxP3+ Regulatory T Cells as Compared to Conventional T Cells after Allogeneic Bone Marrow Transplantation.

Robert Zeiser, MD, Dennis B. Leveson-Gower, Ph.D., Elizabeth A. Zambricki, Jing-Zhou Hou, M.D., Ph.D., Robert Negrin, M.D.

Blood (2006) 108 (11): 448.

DOI: https://doi.org/10.1182/blood.V108.11.448.448

Published: 2006

Journal Articles

Early CD30 signaling is critical for adoptively transferred CD4 + CD25 + regulatory T cells in prevention of acute graft-versus-host disease

Robert Zeiser, Vu H. Nguyen, Jing-Zhou Hou, Andreas Beilhack, Elizabeth Zambricki, Martin Buess, Christopher H. Contag, Robert S. Negrin

Blood (2006) 109 (5): 2225–2233.

DOI: https://doi.org/10.1182/blood-2006-07-038455

Published: 2006

NARROW

Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study

Dose Reductions and Discontinuations with Chronic Lymphocytic Leukemia (CLL) Patients Receiving Ibrutinib in Community and Academic Settings

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy

Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia

Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study

Phase 2 Study of Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Outcomes of Hematopoietic Cell Transplantation in Patients with Refractory Acute Myeloid Leukemia

A Randomized Clinical Trial of Lenalidomide and Dexamethasone with and without Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Interim Study Results,

Differential impact of mammalian target of rapamycin inhibition on CD4 + CD25 + Foxp3 + regulatory T cells compared with conventional CD4 + T cells

Selective Expansion of Human Regulatory (CD4+CD25+CD127LowFOXP3+) Cells to High Purity by Inhibiting Expansion of CD4+CD25+CD127HighFOXP3-Conventional T Cells with Rapamycin.

Early CD30 Signaling Is Critical for Adoptively Transferred CD4 + CD25 + Regulatory T Cells in Prevention of Acute Graft Versus Host Disease.

Impact of mTOR Inhibition on FoxP3+ Regulatory T Cells as Compared to Conventional T Cells after Allogeneic Bone Marrow Transplantation.

Early CD30 signaling is critical for adoptively transferred CD4 + CD25 + regulatory T cells in prevention of acute graft-versus-host disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only